Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Oversold Stochastic | Weakness | -2.01% | |
| Slingshot Bearish | Bearish Swing Setup | -3.73% | |
| Stochastic Buy Signal | Bullish | -3.73% | |
| Lower Bollinger Band Walk | Weakness | -3.73% | |
| Gapped Down | Weakness | -3.73% | |
| Oversold Stochastic | Weakness | -3.73% | |
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakdown | about 3 hours ago |
| Down 5% | about 3 hours ago |
| Down 3% | about 4 hours ago |
| Fell Below Previous Day's Low | about 4 hours ago |
| Down 2 % | about 4 hours ago |
Get a Trading Sidekick!
- Earnings date: 11/04/2024
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Seizure Neuroendocrine Tumors Parkinson’s Disease Gabaa Receptor Positive Allosteric Modulators Neuroendocrine Tumor Anaphylaxis Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.23 |
| 52 Week Low | 1.84 |
| Average Volume | 1,440,796 |
| 200-Day Moving Average | 3.93 |
| 50-Day Moving Average | 4.99 |
| 20-Day Moving Average | 5.12 |
| 10-Day Moving Average | 4.86 |
| Average True Range | 0.34 |
| RSI (14) | 45.05 |
| ADX | 14.87 |
| +DI | 19.19 |
| -DI | 19.36 |
| Chandelier Exit (Long, 3 ATRs) | 4.78 |
| Chandelier Exit (Short, 3 ATRs) | 5.38 |
| Upper Bollinger Bands | 5.87 |
| Lower Bollinger Band | 4.36 |
| Percent B (%b) | 0.25 |
| BandWidth | 29.51 |
| MACD Line | -0.09 |
| MACD Signal Line | -0.02 |
| MACD Histogram | -0.0716 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.10 | ||||
| Resistance 3 (R3) | 5.11 | 5.00 | 5.04 | ||
| Resistance 2 (R2) | 5.00 | 4.90 | 4.99 | 5.02 | |
| Resistance 1 (R1) | 4.87 | 4.84 | 4.81 | 4.86 | 5.00 |
| Pivot Point | 4.75 | 4.75 | 4.72 | 4.75 | 4.75 |
| Support 1 (S1) | 4.62 | 4.66 | 4.56 | 4.61 | 4.47 |
| Support 2 (S2) | 4.51 | 4.60 | 4.50 | 4.45 | |
| Support 3 (S3) | 4.38 | 4.51 | 4.43 | ||
| Support 4 (S4) | 4.37 |
